Suneel L. Mahajan
Nessuna posizione attualmente
Profilo
Suneel L.
Mahajan served as an Independent Director at Multivir, Inc. before obtaining a doctorate degree from B.J.
Govt.
Medical College & Sassoon General Hospitals.
Precedenti posizioni note di Suneel L. Mahajan
| Società | Posizione | Fine |
|---|---|---|
Multivir, Inc.
 Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Direttore/Membro del Consiglio | - |
Formazione di Suneel L. Mahajan
| B.J. Govt. Medical College & Sassoon General Hospitals | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Multivir, Inc.
Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Health Technology |
- Borsa valori
- Insiders
- Suneel L. Mahajan
